Topas Therapeutics GmbH, a Hamburg, Germany-based early stage therapeutics company, closed its €14m ($15.75m) Series A financing round.
The round was led by Epidarex Capital with participation from EMBL Ventures, Gimv and Evotec AG.
The company intends to use the funds to proceeds to accelerate its proprietary tolerance induction platform and to progress with its product development to POC stage in multiple autoimmune and inflammatory indications including multiple sclerosis.
Led by Timm Jessen, CEO, Topas Therapeutics Topas uses nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen specific immune tolerance in the liver.
The platform has been exclusively licensed from the University Medical Center Hamburg-Eppendorf where it was invented by Johannes Herkel, Jörg Heeren and other colleagues in Hamburg.
It is anticipated that Topas will advance their initial program targeting multiple sclerosis into clinical development in 2017.